Core Viewpoint - Spring Medical (688236) is focusing on enhancing its core orthopedic consumables business, increasing R&D investment, and optimizing its product line to improve market competitiveness [2][4]. Company Announcements - The fifth meeting of the fifth board of directors approved four key proposals, including the "2025 Quality Improvement and Efficiency Recovery" action plan and the appointment of a new financial director [1][4]. - The supervisory board approved the reappointment of Da Xin Accounting Firm as the financial auditing and internal control auditing institution for 2025 [1][4]. 2025 Action Plan - Spring Medical aims to deepen its focus on the entire orthopedic product line, develop high-value-added products, and advance R&D in various areas including shoulder and elbow joints, small joints, spine, sports medicine, and trauma [2][4]. - The company plans to accelerate R&D in new fields such as dental care, PRP preparation systems, and robotics, while expanding into international markets to enhance brand recognition [2]. - The company will improve its governance structure, enhance management efficiency, and strengthen internal controls, while also focusing on shareholder returns through reasonable profit distribution policies and H-share buybacks [2][4]. - Spring Medical intends to enhance investor communication and improve the quality of information disclosure, committing to hold at least four performance briefings annually [2].

热度：平均溢价率整体回落，城市间显著分化。 5月平均溢价率回落至7%，一二线城市土拍仍维 持热度，本月平均溢价率仍达到10%，延续了2025年以来的高位。 土地市场延续控量去库存，供应优质宅地占比有望持续提升。 ◎ 文 / 马千里 2025年5月，土地市场成交规模延续量缩价涨态势。据月末快报数据，5月土地成交建筑面积同比下降 18%，成交金额同比增长12%，连续5个月建面回落而金额上升。截至5月25日，本月土地供应建筑面积 4813万平方米，环比上月同期上升10%，同比下降19.3%。本月平均溢价率达到7.2%，环比下降了1.9个 百分点，但北京、上海等核心城市仍成交了多宗高溢价地块，本月一线城市平均溢价率达到13.7%，再度 回到10%以上。5月份以来，中央宏观调控重点着力金融政策稳预期，持续改善行业资金面压力，并发文 推进城市更新，为行业发展带来新的增长动能。 核心要点 供求：面积同比回落而金额增长， 截至2025年5月25日，本月土地供应建筑面积4813万平方米，同 比下降19.3%。成交建筑面积2826万平方米，同比下降18%，成交金额807亿元，同比增长12%。 分布：一二线量价同比均增，三四线量价 ...

今年前4个月，胜利油田鲁胜公司鲁丰采油管理区原油产量超计划运行1844吨，吨油操作成本下降135 元/吨，高风险作业数量同比减少25.8%。成绩的背后，不仅是这家管理区践行"转方式、调结构、提质 量、增效益"系统思维的阶段性成果，更是深化稠油开发方式转型、推进质效变革的生动注脚。 大众新闻记者 顾松 通讯员 孙叶莲 陈军光 如今，技术人员通过系统思维构建全生命周期开发体系，创新"分区增能、冷热并举"模式，在热采低效 区实施转驱转型，实现油井"稳液、稳油、控递减"。去年以来，滨509区块新增转驱井7口，新增转驱储 量84万吨，对应油井从"鸡肋区"华丽变身为"高产田"，7个井组年增油1165吨。 更令人振奋的是滨509-23井的逆袭。经历第12轮蒸汽吞吐302天后，依然保持日产油4.9吨的产能。这样 的"红利"在鲁丰采油管理区并非个例，高效井的运转也见证着油藏开发日益精细化的质变。 少井高效 低耗安全 开发方式的智慧转型，不仅重塑了产量曲线，更催生出"少井高效、低耗安全"的良性循环。 困境下的陡坡突围 年产量计划较前一年增加2500吨，成本指标却要压减30%，高风险作业数量居高不下……"当时就像在 陡坡上推石头上 ...

Core Viewpoint - The company is preparing for the 2024 Annual General Meeting (AGM) to ensure the rights of shareholders and maintain order and efficiency during the meeting [1][2][3] Group 1: Meeting Procedures - Only eligible shareholders, directors, supervisors, senior management, and other attendees can participate in the AGM, and the company reserves the right to refuse entry to those who do not meet the criteria [2] - The meeting will follow the agenda as notified, and no agenda items can be postponed or omitted from voting [2] - Attendees must maintain order and respect the rights of other shareholders during the meeting, with the company authorized to take measures against disruptions [2][3] Group 2: Shareholder Rights - Shareholders have the right to speak, inquire, and vote during the AGM, with a maximum speaking time of five minutes per shareholder [3] - The meeting will be witnessed by a lawyer from a law firm to provide legal opinions on the proceedings [3] Group 3: Financial Performance - The company reported a significant increase in sales revenue, with a 29.7% rise to 194,832 million yuan compared to 150,255 million yuan in the previous year [28][32] - The company managed to reduce its operating loss significantly, with a decrease in net loss attributed to improved sales efficiency and cost control measures [34] - The total assets of the company at the end of 2024 were 1,078,196 million yuan, a decrease from 1,134,287 million yuan in 2023 [28][30] Group 4: Governance and Board Activities - The company completed the election of the fourth board of directors on June 21, 2024, with 14 members, including 5 independent non-executive directors [9][11] - The board held 13 meetings during the reporting period, approving all agenda items without any rejections [10] - The board established four specialized committees to enhance governance efficiency and decision-making [10][12] Group 5: Future Plans - The company plans to apply for financing and credit limits totaling up to 8 billion yuan to support its operational and project development needs [39] - The board aims to strengthen its governance structure and enhance compliance management in 2025 [13]

和元生物技术（上海）股份有限公司 为践行以"投资者为本"的上市公司发展理念，维护公司全体股东利益，增 强投资者信心，促进公司健康可持续发展，和元生物技术（上海）股份有限公司 （以下简称"公司"）基于对公司未来发展前景的信心及内在价值的认可，结合 自身发展战略和经营情况，制定了公司 2025 年度"提质增效重回报"专项行动 方案，以进一步提升公司经营质量效率，保障投资者合法权益，塑造良好的资本 市场形象。具体措施方案如下： 一、聚焦主营业务，提升核心竞争力 公司聚焦并深耕细胞和基因治疗技术服务领域多年，专注于为细胞和基因治 疗的基础研究提供基因治疗载体研制、基因功能研究、药物靶点及药效研究等 CRO 服务；为细胞和基因治疗药物的研发提供工艺开发及测试、IND-CMC 药学研 究、临床样品及商业化产品的 GMP 生产等 CDMO 服务；为再生医学及抗衰领域提 供细胞制备、重组蛋白/外泌体等细胞衍生物生产、细胞存储等技术服务。 近两年来受到创新药行业整体发展波折的影响，公司 CDMO 业务业绩出现亏 损；面对国内生物医药领域面临的新挑战，2025 年度，公司坚持"客户第一" "守 正创新"的经营理念，将积极采取各项 ...

Core Viewpoint - The company has announced its "Quality Improvement and Efficiency Enhancement Return Action Plan" for 2025, aiming to enhance governance, promote high-quality development, and improve market image while addressing recent operational challenges and losses [1][2]. Group 1: Operational Performance - The company reported a net profit loss of 82.1342 million yuan, attributed to a downturn in the macroeconomic environment, reduced client budgets for IT investments, and intensified market competition [1]. - The company is focusing on its core business, adjusting its business structure, and actively exploring new markets, which has impacted cost control [1][2]. Group 2: Innovation and R&D - The company plans to enhance its innovation capabilities by implementing a long-term product strategy and annual R&D plans, with a focus on digital transformation and core technology development [3][4]. - Key product innovations include upgrades to the ASP+ platform and the development of collaborative software and simulation platforms [5]. Group 3: Governance and Compliance - The company is committed to improving its governance structure by optimizing the board composition and enhancing internal control systems to ensure compliance with relevant laws and regulations [6][9]. - A focus on performance management for executives and employees is intended to boost organizational vitality and governance capabilities [3][9]. Group 4: Shareholder Returns - The company has established a three-year dividend plan post-listing, emphasizing the sharing of development results with shareholders while ensuring sustainable growth [6]. - A cash dividend of 18 million yuan was distributed to shareholders for the fiscal year 2023, reflecting the company's commitment to investor returns [6]. Group 5: Investor Communication - The company aims to enhance investor communication by organizing at least three performance briefings annually and utilizing various channels for effective engagement [7][8]. - Efforts will be made to improve the quality of information disclosure, ensuring that key information is easily accessible to investors [8].

人工智能的演进并非线性递进，而是"点面结合、纵横交替"的推进。 人工智能的未来不仅取决于其自身技术的增强，更依赖于如何通过"人工智能+"的路径，与实体经济实现深度融合。在"智能增强"与"人工提质"的双轮驱动 下，人工智能不仅在重塑自身的应用体系，也在重构经济活动的基本单元。其中，"智能增强"依托通用大模型的智能升级，实现了"点"的突破，夯实跨场景 迁移与泛化的技术基础；"人工提质"以行业化、专业化的场景大模型为抓手，推动"面"的拓展，促进技术潜力向经济效益的转化。 进一步来看，人工智能的演进并非线性递进，而是"点面结合、纵横交替"的推进。智能层面的持续增强与应用场景的广泛适配相互赋能，使人工智能在重塑 经济增长路径的同时，进一步重构资源配置方式、组织运行模式与制度治理逻辑，并逐渐成为驱动高质量增长的底层力量。 智能强化：以通用大模型为核心破"点" 通用大模型（如ChatGPT、Claude、Gemini、DeepSeek等）的崛起，标志着人工智能发展迈入以通用智能为核心的关键阶段。这类模型具备跨领域语言理 解、复杂逻辑推理和多模态交互等能力，构建起人工智能系统在不同场景中可迁移、可泛化的底层平台，成为人工智能 ...

Core Viewpoint - The company has implemented a "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan to enhance investor confidence and promote sustainable development, with a focus on core business and innovation in orthopedic products [1][2][5]. Group 1: Business Development and Innovation - The company has been dedicated to the research, production, and sales of orthopedic consumables since its establishment in 1998, continuously expanding its product line and market share both domestically and internationally [1]. - In 2024, the company invested approximately 133 million yuan in R&D, accounting for 16.52% of its revenue, with plans to further enhance its orthopedic product line and diversify its offerings in 2025 [2]. - Several products have become the first or unique in the domestic market, enhancing the company's core competitiveness and industry recognition [3]. Group 2: Product Line Expansion - The company is developing high-value-added products in response to market and clinical needs, including shoulder and elbow joint products, and has received registration approvals for various small joint replacement products [3][4]. - The company is also advancing its dental product solutions and PRP preparation systems, with plans for further innovation in robotic products for joint surgeries [4]. - The company aims to create a diversified revenue matrix through the expansion of its product lines and the optimization of existing business operations [4]. Group 3: Corporate Governance and Management - The company emphasizes the importance of a sound governance structure and effective internal control systems, aligning its development strategy with sustainable business practices [5]. - It has revised its governance policies in accordance with regulatory requirements and is committed to fulfilling its social responsibilities while balancing the interests of all stakeholders [5]. Group 4: Shareholder Returns and Market Confidence - The company has implemented a profit distribution policy that considers industry characteristics and operational stages, with cash dividends of approximately 120 million yuan in 2022 and 138 million yuan in 2023 [6][7]. - The company has actively engaged in H-share buybacks to boost investor confidence and stabilize its stock price, having repurchased 868,145 shares as of June 2024 [7][8]. Group 5: Investor Relations and Information Disclosure - The company prioritizes investor relations management and adheres to legal and regulatory requirements for information disclosure, ensuring transparency and accuracy in communicating its financial and operational status [8][9]. - It aims to enhance the quality of information disclosure and maintain a stable and high-quality investor base to support long-term market confidence [9]. Group 6: Continuous Evaluation and Improvement - The company will continuously assess the implementation of its action plan and focus on core business and cost efficiency to fulfill its responsibilities as a listed company and reward investor trust [9].

近日，4.5万吨铝土矿首次通过"龙烟—大莱龙—海清—胶济—博小"线抵达山东省滨州市无棣县东风港 站，标志着国铁济南局与山东魏桥创业集团有限公司、山东港口烟台港搭建的"烟台西港区至滨州"铝土 矿铁海联运物流大通道正式开通，以"铁路+港口"全链条服务模式有效串联起内陆工厂、临港企业、港 口铁路等各环节，为山东深化交通物流降本提质增效注入新动能。 据介绍，国铁济南局按照"一企一策"原则，大力推进"公转铁""公转水""海铁联运"等运输结构调整，加 强集疏港重点货源组织，增加铁路运量。结合客户实际需求，国铁济南局与山东港口烟台港密切协作， 为客户量身定制以"海铁联运"为基础的多式联运全程物流方案，打通"烟台西港区至滨州"铝土矿铁海联 运物流大通道，为山东西部氧化铝企业提供安全、稳定、绿色、高效、经济的综合物流服务，实现内陆 企业、铁路、港口多方共赢。 今年以来，铁路部门大力发展物流总包服务，推动大宗货物运输"公转铁"，4月份新签订物流总包合同 114个，合同运量2.16亿吨，同比分别增长159%、350%，探索开行"豫焦鲁煤"等重来重去物流总包大宗 班列，充分利用运力资源，提升运输综合效能。与航运企业扩大合作，开发多式 ...

火爆的市场从来都离不开优质的供给。不少年轻观众，尤其是"Z世代"将其对凤凰传奇的喜爱称为"血脉 觉醒"，小时候觉得"土"的歌曲，如今却蜕变为年轻人标榜个性的时尚符号。这一方面是艺人或其公司 团队主动靠近年轻群体，在年轻群体聚集的互联网平台社区中再创作、打破刻板印象；另一方面，文艺 作品带有民族元素，旋律优美、朗朗上口，年轻受众虽然带着"我是什么时候学会了唱他们的歌"的疑 问，但最终在现场收获了一场酣畅淋漓的情绪共鸣和紧接而来的社交媒体谈资，由此也进一步增强了一 场即时消费带来的体验感与获得感。 如此火爆程度，正是近年来国内演唱会市场的缩影。中国演出行业协会统计数据显示，2024年，全国大 型演唱会票房突破260亿元，同比增长78.1%；观众人数超过2900万人次，同比增长45%。 与实物商品相比，服务无形、质量不可见，监管也更有难度。在当前不少热门演出供不应求的情况下， 如何维护有序市场、加力打击"黄牛"高价炒票现象、规范退改票规定等，也是未来强化监管、优化消费 环境需持续努力的方向。 近期，多场演唱会引发观众在社交平台"刷屏"。就在上周，凤凰传奇北京"鸟巢"演唱会观演人数破纪 录，据凤凰传奇主唱杨魏玲花现场 ...